Zogenix and Desitin Announce Filing for European Regulatory Approval of SUMAVEL(TM) D...(esentatives and partner companies in the...),Health

"SUMAVEL DosePro is a unique new product which we believe has broad global appeal," said Roger Hawley, chief executive officer and director of Zogenix. "With FDA approval and commercial manufacturing in place, Desitin's achievement of this milestone in Europe with SUMAVEL DosePro will attract the attention of other companies who may be interested in our technology for delivery of their drugs in other therapeutic areas, including biologics."

About Migraine

Migraine is considered the most common neurological condition in the developed world. It is typically characterized by severe, recurring head pain, usually located on one side of the head and one or more of the following associated symptoms: nausea; vomiting; and increased sensitivity to light, sound and/or smell. Oral and nasal treatment options are available but often do not work quickly enough for patients who experience migraine episodes associated with sudden onset, waking, nausea or vomiting. While needle-based treatment options are associated with faster onset of relief, some patients are deterred from use due to needle-aversion and complicated delivery systems.

About SUMAVEL DosePro

Zogenix plans to launch SUMAVEL DosePro in the US in January 2010, with their US co-promotion partner, Astellas.

SUMAVEL DosePro (sumatriptan injection) is indicated for the acute treatment of migraine attacks, with or without aura, and the acute treatment of cluster headache episodes.

SUMAVEL DosePro should only be used where a clear diagnosis of migraine or cluster headache has been established. SUMAVEL DosePro is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine and should not be administered intravenously. For a gi
'/>"/>